Small-Molecule Inhibitor PD-1/PD-L1 Interaction for Colorectal Cancer Treatment

Abstract

Inhibition of the PD-1/PD-L1 pathway is a target for the development of new therapies. US10710986 patent describes a small molecule that targets PDL-1/PD-1 interactions and triggers antitumor activity against colorectal cancer. However, it does not describe biological assays that allow us to suppose that this small molecule may be active in other types of cancer. So far, there are no reports of clinical trials to evaluate the safety, toxicity and efficacy, but it will be of great interest to analyze in the future if this compound surpasses the action of therapy in cancer.

Keywords:

• cancer
• immunotherapy
• PD-1
• PD-L1
• small molecule

Acknowledgments

The authors would like to thank I Herrera for the critical analysis of the design of the patent evaluation. The authors thank the Mexican people for the support, through their taxes, provided for the development of this article.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.